SNAPPER: Prospective Evaluation of Renal effects
We are inviting you to take part in this sub study because you have joined the SNAP platform or registry, and you have a risk factor for developing injury to your kidneys.
This sub-study is being conducted in Australia.
Lead Investigator: Amy Legg - Brisbane Women's Hospital, Menzies School of Health
Email: amytherese.legg@menzies.edu.au
Please read the below information to learn more about the assessments and tests involved in this sub-study.
We will also be using results from your blood tests that are already being done by the hospital. We will not take any additional blood tests from you.
Risks:
Benefits:
You can withdraw from the sub study and/or from future use of your samples at any time, just notify a member of the SNAP study team.
If you withdraw, we will keep any information we have collected about you up until you withdraw. If you do not agree with this, you should not join this substudy.
SNAP Trial
Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.
Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia
Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia